This is the authors' abstract. We don't add key points for this paper.
The purpose of this article is to provide clinicians with answers to some of the most important and frequently asked questions related to smallpox vaccination. Information that has direct bearing on this issue is broad in scope, complex, and multidisciplinary, and this article is offered as an attempt to distil this information into a single accessible resource. The information is organized as questions and answers and grouped in the following major sections: Purpose and Approach of the US Smallpox Vaccination Program, Description of the Current Vaccine and Vaccine Supply, Efficacy and Duration of Immunity Following Vaccination, Vaccine Administration, Vaccine Safety and Adverse Reactions, Contraindications to Smallpox Vaccination, Treatment of Vaccine-Related Complications, Liability Issues Related to Smallpox Vaccination, and The Recent Israeli Smallpox Vaccination Series. Why has the President of the United States initiated a smallpox vaccination program in 2002–3? This is answered by relevant excerpts from the President's announcement of this program, from 13 December 2002:
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Bartlett et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: